Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

At the 2026 EASD meeting, Eli Lilly reported that 34.9% of patients receiving the highest retatrutide dose lost at least 25% of body weight, while its EloraTZP combination delivered up to 23.3% weight loss in obesity patients with type 2 diabetes. Novo Nordisk cited real-world evidence that Ozempic was associated with a 6% lower risk of major cardiovascular events versus Lilly's Mounjaro. The data reinforce a rapidly expanding GLP-1 market projected to exceed $100 billion by 2030, supporting diversified exposure through GLP-1-focused ETFs such as OZEM, HRTS and THNR.

Analysis

The key investable shift is from a capacity-constrained duopoly to efficacy-, convenience- and reimbursement-driven segmentation. LLY retains the strongest near-term pricing umbrella if its next-generation regimen converts trial efficacy into tolerability and persistence, but superior efficacy can also accelerate payer demands for outcomes-based rebates; the revenue upside need not translate one-for-one into margins. NVO's cardiovascular-outcomes narrative is strategically valuable because it can defend formulary access even if its weight-loss efficacy gap widens, making relative prescription and net-price trends more important than headline trial comparisons over the next 1-3 months.

The less-consensus beneficiary is the clinical-development and commercialization ecosystem rather than the small thematic ETFs. CROs such as IQV and MEDP could see sustained obesity-study activity, while specialty pharmacies/telehealth platforms face a mixed outcome: oral adoption expands addressable demand but may reduce the friction and service intensity that support dispensing economics. OZEM and THNR are too small for institutional-sized execution and their concentrated, overlapping holdings offer little diversification versus a deliberately sized LLY/NVO pair.

Consensus is likely underestimating the risk that broad efficacy improvements compress category economics over 6-18 months. More viable oral and long-acting alternatives increase payer bargaining power, raise promotional spending and make discontinuation, adverse-event and lean-mass data central to valuation; this favors balance sheets and established market access over earlier pipeline optionality. A reversal signal would be worsening gross-to-net trends, slower refill persistence, or formulary exclusions in the next two quarterly reporting cycles—not an isolated conference data release.

Key Decisions for Investors

• Initiate a 3-6 month long LLY / short NVO dollar-neutral pair only on a pullback in the relative spread; thesis is LLY's nearer-term volume and mix leverage versus NVO's likely price-defense burden. Target 10-15% relative return; exit if LLY reduces obesity supply or revenue guidance, or if NVO demonstrates sustained prescription-share stabilization plus improving net pricing.
• Maintain AMGN as a small, catalyst-driven 6-12 month long rather than a core GLP-1 substitute: differentiated dosing and mechanism can create upside if persistence/tolerability data validate, but size at half a typical large-pharma position given binary clinical and commercial risk. Falsifier: data fail to show competitive durability or management signals a non-viable commercial profile.
• Avoid adding exposure through THNR or OZEM for institutional deployment; use liquid single names or a broad healthcare sleeve instead. Monitor fund premiums/discounts and creation activity as a sentiment indicator, since limited assets can amplify retail-flow volatility without changing underlying earnings.
• Keep PFE and REGN on a watchlist rather than chase obesity optionality. Upgrade only after disclosed Phase 2/3 dose-selection, discontinuation and manufacturing-cost data permit a credible probability-weighted sales model; absent those inputs, their obesity narratives are unlikely to drive durable multiple expansion.